NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration with Gustave Roussy Cancer Campus in Paris to perform genetic testing to identify therapeutically relevant alterations in cancer-related genes.

New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, will use its proprietary diagnostic platform called Neo as part of the agreement. Neo allows rapid sample processing that is compatible with daily clinical routine and standard sample material such as formalin-fixed, paraffin-embedded tissue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.